GlassScriptPhysician profile
Brittany Sleek
NPI 1669982088
$5,000.59
in general payments reported to CMS, 2019-2025
30 companies · $1,336 in 2025
The $1,336 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,443 · 2022: $1,068 · 2023: $560 · 2024: $595 · 2025: $1,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,490.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,076.15 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,020.72 | 2021-2025 | |
| Pfizer INC. | $507.75 | 2021-2025 | |
| Lilly USA, LLC | $416.44 | 2021-2025 | Mounjaro, Zepbound, Kisunla |
| Amgen INC. | $397.33 | 2021-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $203.48 | 2021-2023 | Bexsero |
| Novartis Pharmaceuticals Corporation | $186.12 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $140.31 | 2021-2025 | Airsupra |
| Amarin Pharma, INC. | $113.76 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $112.11 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $97.27 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.95 | 2021-2024 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $81.96 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $74.55 | 2021-2024 | Trintellix |
| Dexcom, INC. | $74.32 | 2024-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $69.51 | 2021-2023 | Veozah |
| Jazz Pharmaceuticals INC. | $46.30 | 2021-2022 | |
| Lundbeck LLC | $38.69 | 2023-2024 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $37.24 | 2021 | |
| Janssen Pharmaceuticals, INC | $28.63 | 2021 | |
| Abbott Laboratories | $22.93 | 2023 | Freestyle Libre 3 |
| Covis Pharma Gmbh | $22.60 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.50 | 2022 | |
| Shield Therapeutics INC | $20.39 | 2022 | |
| Paratek Pharmaceuticals, INC. | $18.21 | 2022 | |
| Eisai INC. | $17.49 | 2021 | |
| Amneal Pharmaceuticals LLC | $17.32 | 2022 | |
| Mylan Specialty L.P. | $15.82 | 2022 | |
| Sunovion Pharmaceuticals INC. | $15.57 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Sleek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.